Answers are grounded in this paper and cite their sources.
Neurodegenerative diseases including Alzheimer's, Parkinson's, and Huntington's offer serious health issues to people all over the world, due to their progressive nature and lack of effective therapies. In order to improve patient outcomes and allow for prompt action to limit the progression of the disease, early identification is essential. With a focus on deep learning methods, this study investigates the use of AI-powered analysis of medical images for the early detection of neurodegenerative disorders. The use of several medical imaging modalities, such as PET, CT, and MRI, in identifying disease biomarkers at an early stage is investigated. The usefulness of deep learning techniques to automate feature extraction, categorize illness states, and track disease progression is highlighted. These techniques include convolutional neural networks [CNNs], recurrent neural networks [RNNs], and generative adversarial networks [GANs]. The study also discusses the difficulties in using AI implementation, including data quality, image variability, and the interpretability of AI models. Furthermore, the study explores possible regulatory and ethical considerations in clinical adoption. It also examines AI's growing role in clinical settings and its ability to work with personalized medicine which present promising opportunities for improving the diagnosis and management neurodegenerative disease. The final section of this paper outlines important future directions for increasing the use of AI in clinical care, including multi-modal fusion and transfer learning.
No takes yet. Share an insight, caveat, or question.
Fanijo et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: